

1 **High seroprevalence of *Leishmania infantum* is linked to immune activation in**  
2 **people with HIV: a two-stage cross-sectional study in Bahia, Brazil**

3

4 Laise de Moraes<sup>1,2</sup>, Luciane Amorim Santos<sup>1,2,3</sup>, Liã Bárbara Arruda<sup>4</sup>, Maria da  
5 Purificação Pereira da Silva<sup>5</sup>, Márcio de Oliveira Silva<sup>5</sup>, José Adriano Góes Silva<sup>1,2,5</sup>,  
6 André Ramos<sup>5</sup>, Marcos Bastos dos Santos<sup>2</sup>, Felipe Guimarães Torres<sup>2</sup>, Cibele Orge<sup>2</sup>,  
7 Antonio Marcos Teixeira<sup>2</sup>, Thiago Vieira<sup>2</sup>, Laura Ramírez<sup>6</sup>, Manuel Soto<sup>6</sup>, Maria  
8 Fernanda Rios Grassi<sup>2,3</sup>, Isadora Cristina de Siqueira<sup>2</sup>, Dorcas Lamounier Costa<sup>7</sup>, Carlos  
9 Henrique Costa<sup>7</sup>, Bruno de Bezerril Andrade<sup>2,3</sup>, Kevan Akrami<sup>1,2</sup>, Camila Indiani de  
10 Oliveira<sup>1,2,3</sup>, Viviane Sampaio Boaventura<sup>1,2,8</sup>, Manoel Barral-Netto<sup>1,2</sup>, Aldina Barral<sup>1,2\*</sup>,  
11 Anne-Mieke Vandamme<sup>9\*</sup>, Johan Van Weyenbergh<sup>9\*</sup>, Ricardo Khouri<sup>1,2,9</sup>

12

13 1 Programa de Pós-graduação em Ciências da Saúde, Faculdade de Medicina da Bahia,  
14 Universidade Federal da Bahia, Salvador, Brazil.

15 2 Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.

16 3 Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil.

17 4 Centre for Clinical Microbiology, Division of Infection & Immunity, University  
18 College London, London, United Kingdom.

19 5 Centro Estadual Especializado em Diagnóstico, Assistência e Pesquisa, Secretaria de  
20 Saúde do Estado da Bahia, Salvador, Brazil.

21 6 Departamento de Biología Molecular, Facultad de Ciencias, Centro de Biología  
22 Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad  
23 Autónoma de Madrid, Madrid, Spain.

24 7 Laboratório de Leishmanioses, Instituto de Doenças Tropicais Natan Portella,  
25 Universidade Federal do Piauí, Teresina, Brazil.

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

26 8 Hospital Santa Izabel, Salvador, Brazil.

27 9 Department of Microbiology, Immunology and Transplantation, Rega Institute for

28 Medical Research, Clinical and Epidemiological Virology, KU Leuven, Leuven,

29 Belgium.

30

31 \*equal contribution

32

33 **Short title:** *Leishmania* seropositivity linked to immune activation in people with HIV

34 **ABSTRACT**

35 **Background:** Visceral leishmaniasis is an opportunistic disease in HIV-1 infected  
36 individuals, although not yet recognized as a determining factor for AIDS diagnosis. The  
37 growing geographical overlap of HIV-1 and *Leishmania* infections is an emerging  
38 challenge worldwide, as co-infection increases morbidity and mortality for both. Here,  
39 we determined the prevalence of people living with HIV (PWH) with a previous or  
40 ongoing infection by *Leishmania infantum* in Bahia, Brazil and investigated the  
41 virological and immunological factors associated with co-infection.

42

43 **Methodology and Principal Findings:** We adopted a two-stage cross-sectional cohort  
44 (CSC) design (CSC-I, n=5,346 and CSC-II, n=317) of treatment-naïve HIV-1-infected  
45 individuals in Bahia, Brazil. In CSC-I, samples collected at the time of HIV-1 diagnosis  
46 between 1998 and 2013 were used for serological screening for leishmaniasis by an in-  
47 house immunoassay (ELISA) with SLA (Soluble Leishmania Antigen), resulting in a  
48 prevalence of previous or ongoing infection of 16.27%. Next, 317 PWH were  
49 prospectively recruited from July 2014 to December 2015 with collection of  
50 sociodemographic and clinical data. Serological validation by two different  
51 immunoassays confirmed a prevalence of 15.46% and 8.20% by anti-SLA, and anti-  
52 HSP70 serology, respectively, whereas 4.73% were double-positive (DP). Stratification  
53 of these 317 individuals in DP and double-negative (DN) revealed a significant reduction  
54 of CD4<sup>+</sup> counts and CD4<sup>+</sup>/CD8<sup>+</sup> ratios and a tendency of increased viral load in the DP  
55 group, as compared to DN. No statistical differences in HIV-1 subtype distribution were  
56 observed between the two groups. However, we found a significant increase of  
57 CXCL10/IP-10 ( $p=0.0076$ ) and a tendency of increased CXCL9/MIG ( $p=0.061$ ) in  
58 individuals with DP serology for *L. infantum*, demonstrating intensified immune

59 activation in this group. These findings were corroborated at the transcriptome level in  
60 independent *Leishmania*- and HIV-1-infected cohorts (Swiss HIV Cohort and Piaui  
61 Northeast Brazil Cohort), indicating that *CXCL10* transcripts are shared by the IFN-  
62 dominated immune activation gene signatures of both pathogens and positively correlated  
63 to viral load in untreated PWH.

64

65 **Conclusions/Significance:** This study demonstrated a high prevalence of PWH with *L.*  
66 *infantum* seropositivity in Bahia, Brazil, linked to IFN-mediated immune activation and  
67 a significant decrease in CD4<sup>+</sup> levels. Our results highlight the urgent need to increase  
68 awareness and define public health strategies for the management and prevention of HIV-  
69 1 and *L. infantum* co-infection.

70

## 71 AUTHOR SUMMARY

72 More than 1 billion people live in areas endemic for leishmaniasis and are at risk of  
73 infection, which includes one third of the 38 million people living with HIV (PWH)  
74 worldwide. Leishmaniasis is a neglected tropical disease caused by infection with  
75 *Leishmania* parasites, transmitted by bites from infected sand flies. HIV/*Leishmania* co-  
76 infection is increasing worldwide, especially in Southern Europe and Brazil, due to both  
77 human and ecological factors (migration, climate change, deforestation). This study  
78 demonstrates that a worryingly high number (one out of 6) of PWH in Bahia (Northeast  
79 Brazil) show previous or ongoing infection with the parasite *Leishmania infantum*,  
80 determined by antibodies detection against this parasite in PWH. Using a rigorous study  
81 design with data collection over 18 years in >5500 PWH, we found similarly high  
82 numbers (16.3% and 15.5%) of PWH with antibodies against *Leishmania infantum* in two  
83 consecutive cohorts. Moreover, PWH with antibodies against *Leishmania infantum* in  
84 Bahia, Brazil displayed a worse immune profile, with lower CD4 immune cells numbers  
85 and immune activation mediated by interferon, which we confirmed in independent HIV-  
86 and *Leishmania*-infected cohorts from other geographic areas. Our results underscore the  
87 need to raise awareness and define public health strategies to prevent HIV/*Leishmania*  
88 co-infection, since therapeutic failure and mortality are strongly increased in co-infected  
89 PWH, even with antiretroviral therapy as standard of care.

## 90 INTRODUCTION

91 HIV is the etiological agent of Acquired Immunodeficiency Syndrome (AIDS), a slowly  
92 progressive disease characterized by chronic immune activation resulting from the loss  
93 of cell-mediated immune function [1,2]. Host genetic factors (e. g. HLA genotypes) and  
94 host immune response (e.g. release of proinflammatory cytokines and chemokines), as  
95 well as the presence of co-infections, can directly influence the rate of disease progression  
96 [2–4].

97

98 Neglected Tropical Diseases (NTDs) are endemic among the most impoverished  
99 populations in Africa, Asia and Latin America. Among these NTDs, visceral  
100 leishmaniasis (VL), caused by infection with *Leishmania infantum*, is associated with  
101 increased morbidity and mortality in people with HIV-1 (PWH) but has not been  
102 recognized as a diagnostic criterion for AIDS [5]. The World Health Organization (WHO)  
103 identified the geographical overlap of both infections as an emerging challenge in  
104 successfully controlling the HIV-1 infection in countries considered endemic for  
105 leishmaniasis, such as Brazil [6].

106

107 The few studies evaluating the prevalence of HIV-1 and *L. infantum* coinfection on a  
108 national level in Brazil [7,8] have highlighted regions endemic for leishmaniasis: Distrito  
109 Federal [9], Ceará [10,11], Maranhão [12,13], Mato Grosso [14], Mato Grosso do Sul  
110 [15,16], Minas Gerais [17,18], Pernambuco [19], Piauí [20], Rio Grande do Norte [21,22],  
111 Sergipe [23] and Tocantins [24]. Bahia is also considered an endemic area for  
112 leishmaniasis, with an incidence rate of 0.08/10,000 inhabitants for VL reported in 2018  
113 [25]. In addition, the increase of geographical overlap between HIV-1 and *Leishmania*  
114 infection in Bahia [25,26] has raised public health concerns. However, no

115 epidemiological studies have attempted to investigate the prevalence of co-infection to  
116 date. Therefore, we investigated the seroprevalence of *L. infantum* in PWH in the state of  
117 Bahia, Brazil and attempted to identify virological and immunological factors associated  
118 with co-infection, supported by publicly available transcriptomic data.


## 119    **METHODOLOGY**

### 120    **Study population and design**

121    A two-stage cross-sectional cohort study (CSC-I, 1998-2013 and CSC-II, 2014-2015) was  
122    designed to determine the seroprevalence of *L. infantum* in PWH and to evaluate the  
123    association with demographic, clinical, virological and immunological parameters  
124    (Figure 1). From 1998 to 2015, individuals with a new confirmed diagnosis of HIV-1 at  
125    the Specialized Center for Diagnosis, Care and Research (CEDAP), a state government  
126    public health reference service located in the city of Salvador, Bahia-Brazil, were  
127    included in this study. Their remaining blood sample was utilized for the outlined assays  
128    herein. First, serological reactivity to *L. infantum* was assessed in plasma or serum  
129    samples from the retrospective cross-sectional cohort (n=5,346) collected between 1998  
130    and 2013. In the second stage, serological reactivity to *L. infantum* was assessed in a  
131    prospective cross-sectional cohort of 317 PWH (sampled between July 2014 and  
132    December 2015), with demographic and clinical data (sex, age, HIV-1 viral load, CD4+,  
133    CD8+, CD4/CD8 ratio and CD45+ T cell counts) prospectively obtained from the clinical  
134    records. Additionally, we performed a subpopulation analysis on a subset of PWH  
135    identified as either double-positive or double-negative using two independent anti-  
136    *Leishmania* immunoassays. Based on these stringently defined categories, we compared  
137    virological and immunological factors influenced by *L. infantum* seropositivity. The  
138    study's recruitment did not interfere with standard medical care, and patients were treated  
139    according to the general Brazilian/WHO guidelines. This study was conducted following  
140    the Declaration of Helsinki and was approved by the Institutional Review Board of the  
141    Gonçalo Moniz Institute (IGM-FIOCRUZ) (protocol number 1.764.505).

142





143

144 **Figure 1. Flow chart of study design detailing the two-stage cross-sectional and**  
145 **prospective cohort study among people living with HIV in Bahia, Brazil.**

146

### 147 **Detection of anti-*Leishmania* and anti-*Trypanosoma* antibodies**

148 All samples underwent a previously described and validated in-house enzyme-linked  
149 immunosorbent assay (ELISA) for the detection of IgG against Soluble *Leishmania*  
150 *infantum* Antigen (SLA), which we previously demonstrated as a sensitive biomarker  
151 (90% sensitivity and 95% specificity) of current or past infection with the parasite [27].  
152 SLA preparation and ELISA procedures were performed as previously described [28].  
153 For the prospective cohort of 317 samples from PWH with digitalized clinical records,  
154 results of the SLA immunoassay were compared with a second, previously described  
155 ELISA employing recombinant *L. infantum* heat shock protein 70 (HSP70), for which we  
156 once found a sensitivity of 74% and a specificity of 73% [29]. To avoid false-positive  
157 results for *L. infantum* due to cross-reactivity among Trypanosomatidae parasites, an  
158 ELISA for anti-*Trypanosoma cruzi* IgG (Euroimmun) was employed in a subset of 42

159 samples with dual-positive (DP) (n=15) and double-negative (n=27) serology for anti-  
160 SLA and anti-HSP70.

161

### 162 **Control samples and ELISA cutoff value**

163 Positive (n=6) *Leishmania*-infected patient samples and negative (n=47) control samples  
164 previously identified by the intradermal Leishmanin (also known as Montenegro)  
165 Delayed-type Hypersensitivity (DTH) skin test, with clinical and laboratorial  
166 confirmation, were used to establish anti-SLA and anti-HSP70 ELISA cutoff values. For  
167 each assay, specific cutoff values were determined using the mean OD values obtained  
168 from the included negative samples plus three times the observed standard deviation, with  
169 each assay's index values corresponding to the OD/cutoff ratio (Supplementary Figure 1).

170

### 171 **Quantification of immunological markers**

172 A Cytometric Bead Array (CBA) Human Inflammatory Cytokines Kit (BD Biosciences)  
173 was employed to quantify plasma concentrations of IL-1 $\beta$ , IL-6, IL-10, IL-12p70 and  
174 TNF, while CCL2/MPC-1, CCL5/RANTES, CXCL8/IL-8, CXCL9/MIG and  
175 CXCL10/IP-10 quantification was performed using a CBA Human Chemokine Kit (BD  
176 Biosciences), each following the manufacturer's instructions. Data acquisition and  
177 analysis were performed using a FACSArray Bioanalyzer (BD Biosciences) and FlowJo  
178 v.10.0.5 (Tree Star) software, respectively.

179

### 180 **HIV-1 sequencing analyses**

181 Viral RNA isolation was performed using a QIAamp Viral RNA Mini Kit (QIAGEN)  
182 following the manufacturer's instructions. The protease/reverse transcriptase (PR/RT)  
183 region was amplified and sequenced as previously described [30]. Outer polymerase

184 chain reaction (PCR) was performed using a SuperScript III One-Step RT-PCR System  
185 with Platinum Taq DNA Polymerase (Thermo Fisher Scientific) and the following  
186 primers: K1 (CAGAGCCAACAGCCCCACC) and K2  
187 (TTTCCCCACTAACTTCTGTATGTCATTGACA) [31]. Inner PCR was performed  
188 using Platinum Taq DNA Polymerase High Fidelity (Thermo Fisher Scientific) with the  
189 following primers: DP16 (CCTCAAATCACTCTTTGGCAAC) and RT4  
190 (AGTTCATAACCCATCCAAAG) [32]. The generated inner PCR products were  
191 sequenced using a BigDye Terminator v.3.1 Cycle Sequencing Kit (Applied Biosystems)  
192 with capillary electrophoresis run on an ABI 3500xL Genetic Analyzer (Applied  
193 Biosystems) employing the following primers: F1 (GTTGACTCAGATTGGTTGCAC),  
194 F2 (GTATGTCATTGACAGTCCAGC) [33], DP10  
195 (CAACTCCCTCTCAGAAGCAGGAGCCG), DP11  
196 (CCATTCCTGGCTTTAATTTACTGGTA) [34], RT4  
197 (AGTTCATAACCCATCCAAAG), GABO1 (CTCARGACTTYTGGGAAGTTC) and  
198 GABO2 (GCATCHCCCACATCYAGTACTG) [30]. Sequence visualization, editing  
199 and assembly were performed using Geneious v.10.0.8 (Biomatters) software. HIV-1  
200 subtyping was determined using the REGA HIV-1 Subtyping Tool v.3.4.1  
201 (<https://www.genomedetective.com/app/typingtool/hiv>) and the jpHMM-HIV approach  
202 [35]. Phylogenetic analysis was conducted using HIV-1 subtype references retrieved from  
203 the Los Alamos HIV sequence database  
204 (<https://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html>) (Supplementary  
205 Table 1). Phylogenetic inference was performed using PhyML v.3.0 [36], applying the  
206 BIONJ method and using the General Time Reversible (GTR) nucleotide substitution  
207 model with 1,000 bootstrap replicates.  
208

209 **Transcriptome and systems biology analysis**

210 Transcriptome analysis of publicly available data was performed as recently described  
211 [37–39]. Overlap ratio was calculated as:  $k/K = \# \text{ Genes in Overlap (k)} / \# \text{ Genes in Gene}$   
212  $\text{Set (K)}$  using Molecular Signatures Database (MSigDb). HIV-1 (Swiss HIV Cohort,  
213  $n=137$ ) [40] and *Leishmania*-infected individuals (Piaui Northeast Brazil Cohort,  $n=30$ )  
214 [41] were analyzed using GEO2R from Gene Expression Omnibus (GEO).

215

216 **Statistical analysis**

217 Since data were not normally distributed, as identified by the Shapiro-Wilk and  
218 D'Agostino-Pearson tests (GraphPad Prism v.7.0), results were analyzed using non-  
219 parametric tests: Mann-Whitney test and Spearman's correlation, as well as Fisher's exact  
220 test, with  $p < 0.05$  considered statistically significant.

221 **RESULTS**

222 **Detection of IgG antibodies against *Leishmania (L.) infantum* antigens (anti-SLA**  
223 **and anti-HSP70) in people living with HIV (PWH)**


224 To determine the seroprevalence to *L. infantum* among PWHs, 5,346 plasma or serum  
225 samples from treatment-naïve HIV-1-infected individuals diagnosed between 1998 and  
226 2013 were tested for the presence of IgG antibodies against soluble *L. infantum* antigen  
227 (anti-SLA) (Figure 1).

228


229 Positivity for anti-SLA serology was detected in 870/5,346 samples, resulting in an  
230 prevalence rate of 16.27% (Figure 2). Samples from patients with clinically confirmed  
231 diagnosis of visceral leishmaniasis (VL) and laboratory-confirmed *L. infantum* infection  
232 in the absence (n=16) or presence of HIV-1 co-infection (n=10) were used as an additional  
233 control [42]. As shown in Figure 2A, anti-SLA antibodies were detected in 81.25% and  
234 100% of HIV-1-negative and HIV-1-positive VL patients, respectively. Besides, we  
235 found humoral immune response against SLA in VL patients quantitatively similar  
236 regardless of the presence of HIV-1 co-infection (Mann Whitney p=0.71, HIV-negative  
237 vs HIV-positive). Thus, we could confirm the high specificity of the *L. infantum* anti-  
238 SLA IgG serology protocol employed herein.

239

A



B



240

241 **Figure 2. Detection of anti-*L. infantum* IgG antibodies in plasma/serum samples**

242 **collected from PWH between 1998 and 2013. A) Violin plot with a dot-plot overlay of**

243 **OD index values representative of *L. infantum* anti-SLA serology in the retrospective**

244 **PWH cohort (n=5,346) and a clinical- and laboratory-confirmed control group (HIV-1-**


245 **VL<sup>+</sup>, n=16; and HIV-1<sup>+</sup> VL<sup>+</sup>, n=10). Filled black circles (●): PWH cross-sectional cohort**

246 samples; filled red circles (●): clinical HIV-1 negative controls with VL; filled red squares  
247 with black borders (■): clinical controls with HIV-1 positive controls and VL. B) Pie chart  
248 representation of samples (expressed as percentages) with positive (red) and negative  
249 (gray) anti-SLA *L. infantum* serology.

250

251 Subsequently, to validate our findings, we enrolled an independent prospective CSC  
252 between 2014 and 2015, composed of 317 treatment-naïve HIV-1-infected individuals  
253 from which complete demographic and clinical data were obtained from digitalized  
254 clinical records. Moreover, we combined anti-SLA serology with a second specific assay  
255 to detect IgG antibodies against *L. infantum* HSP70 recombinant protein (anti-HSP70)  
256 (Figure 1). The overall prevalence of anti-SLA positive serology in the prospective cohort  
257 was 15.46% (49/317), similar to the cross-sectional cohort results. The prevalence of anti-  
258 HSP70 positive serology in the prospective cohort was 8.20% (26/317) (Figure 3).  
259 Positivity for both anti-SLA and anti-HSP70 (i.e., double-positivity – DP) was detected  
260 in 4.73% (15/317) of the cohort; anti-SLA positive serology alone was detected in 10.73%  
261 (34/317); anti-HSP70 serology alone in only 3.47% (11/317) and the union of both anti-  
262 SLA and anti HSP70 positive serology was detected in 18.93% (Figure 3D).

263



264

265 **Figure 3. Detection of anti-*L. infantum* IgG antibodies in plasma samples collected**  
266 **from PWH between 2014 and 2015.** A) Violin plot with a dot-plot overlay of OD index  
267 values representative of *L. infantum* anti-SLA and anti-HSP70 serology in the PWH  
268 prospective cohort (n=317). The red symbols represent the DP individual diagnosed with  
269 visceral leishmaniasis >20 years ago. B-C) Pie chart representation (expressed as  
270 percentages) of samples positive for B) *L. infantum* anti-HSP70 (blue) and C) *L. infantum*  
271 anti-SLA (red). Percentages of negative samples are depicted in gray. D) Venn diagram  
272 illustrating overlap in detection between *L. infantum* anti-SLA and anti-HSP70  
273 serological methods.

274

275 Based on these findings, DP (n=15) was adopted as the most stringent criterium for *L.*  
276 *infantum* infection. Assessment of standard diagnosis of previous or ongoing visceral  
277 leishmaniasis (VL) documented in the clinical records showed that one of the 15 DP



278 subjects had VL reported >20 years ago (anti-SLA index=4.71; anti-HSP70 index=2.67).  
279 After two decades of clinical diagnosis, this pronounced humoral response most likely  
280 reflects chronic antigen exposure, supporting the concept that *Leishmania* infection is  
281 lifelong in most patients as observed in murine models of disease [43–45]. These results,  
282 taken together, demonstrated that a significant number of PWH in the state of Bahia are  
283 unaware of their exposure to and/or infection by *L. infantum* and are at risk of developing  
284 new or relapsing visceral leishmaniasis.

285

### 286 **Demographic and clinical markers associated with dual-positive *L. infantum*** 287 **serology in PWH**

288 The CSC-II (n=317) consisted of predominantly young males (72.23%) with a median  
289 age of 32 years old at the time of HIV diagnosis, median viral load of 40,370 copies/mL  
290 (IQR=7,032-141,359), CD4<sup>+</sup> T cell count of 369 cells/ $\mu$ L (IQR=163-609), CD8<sup>+</sup> T cell  
291 count of 1,025 cells/ $\mu$ L (IQR=715-1,441), and CD45<sup>+</sup> T cell count of 2,144 cells/ $\mu$ L  
292 (IQR=1,507-2,763) (Table 1).

293 **Table 1.** Epidemiological, virological and immunological characteristics of PWH in  
294 Bahia (Brazil) between 2014 and 2105, stratified according to DP and DN<sub>total</sub>  
295 Data are expressed as median values, interquartile ranges (IIQ) and numbers of  
296 individuals evaluated (N), or as proportions (%) with the number of individuals evaluated  
297 in parentheses. The Mann-Whitney test was used to determine statistical differences  
298 between DP and DN<sub>total</sub>; *p* values considered statistically significant (*p*<0.05) are shown  
299 in bold. DP: dual-positive; DN<sub>total</sub>: total double-negative; NA: not analyzed

300

	n=317	DP (n=15)	DN <sub>total</sub> (n=257)	<i>p</i> value
Male, n	72.23% (229)	73.33% (11)	70.42% (181)	NA

Age, years	32 (26-41)	41 (30-50)	32 (25-39)	<b>0.0430</b>
HIV-1 viral load, copies/mL	40,370 (7,032-141,359)	64,746 (2,480-532,702)	34,956 (6,330-127,747)	0.1268
CD4 <sup>+</sup> T cell count, cell/ $\mu$ L	369 (163-609)	168 (107-449)	405 (188-641)	<b>0.0208</b>
CD8 <sup>+</sup> T cell count, cell/ $\mu$ L	1,025 (715-1,441)	950 (688-1,546)	1025 (728-1,443)	0.8679
CD4 <sup>+</sup> /CD8 <sup>+</sup> T cell ratio	0.33 (0.14-0.59)	0.21 (0.060-0.37)	0.35 (0.15-0.63)	<b>0.0282</b>
CD45 <sup>+</sup> T cell count, cell/ $\mu$ L	2,144 (1,507-2,763)	1,758 (1,142-3,028)	2,198 (1,585-2,793)	0.3262

---

301

302 Comparative analyses between the DP (n=15) and total double-negative (DN<sub>total</sub>) (n=257)  
303 groups indicated that individuals with antibodies against both SLA and HSP70 *L.*  
304 *infantum* were older (p=0.0430), presented lower baseline CD4<sup>+</sup> T cell counts (p=0.0208)  
305 and lower CD4<sup>+</sup>/CD8<sup>+</sup> T cell ratios (p=0.0282), as well as a tendency towards higher  
306 HIV-1 viral load levels (p=0.1268) suggestive of an advanced stage of HIV-1 infection  
307 than individuals without *L. infantum* antibodies (Table 1). Indeed, a large proportion of  
308 DP individuals (10/15, 66.67%) had <200 CD4<sup>+</sup> T cells/ $\mu$ L at the time of HIV-1  
309 diagnosis, which is considered AIDS-defining.

310

### 311 **Subpopulation analysis reveals virological and immunological markers associated** 312 **with dual-positive *L. infantum* serology in PWH**

313 To ensure specificity for *L. infantum* in the DP serological samples and to exclude the  
314 possibility of cross-reactivity due to polyclonal activation and hypergammaglobulinemia,  
315 anti-*Trypanosoma cruzi* IgG serology was performed. Samples demonstrating positivity  
316 for anti-*T. cruzi* IgG (n=2) were excluded from subsequent analyses (Supplementary  
317 Figure 2). Next, we performed a subpopulation analysis by matching DN individuals to  
318 the DP group by gender, age, viral load and CD4<sup>+</sup> T cell count. This strategy resulted in  
319 the establishment of a third group (DN<sub>paired</sub>) (Figure 1), thereby mitigating the possibility  
320 of bias arising from polyclonal activation, hypergammaglobulinemia, high viral load or  
321 low CD4<sup>+</sup> T cell levels. Controlling for these parameters limited the potential for

322 variations in the HIV-1 transcriptomic profile and the state of immune activation. No  
323 statistical differences were observed between the DP and DN<sub>paired</sub> groups regarding  
324 sociodemographic and clinical parameters, which underscores the pairing strategy's  
325 equity (Table 2).

326

327 **Table 2.** Epidemiological, virological and immunological characteristics of PWH in  
328 Bahia (Brazil) between 2014 and 2105, stratified according to DP and DN<sub>paired</sub>.

329 Data are expressed as median values, interquartile ranges (IIQ) and numbers of  
330 individuals evaluated (N), or as proportions (%) with the number of individuals evaluated  
331 in parentheses. The Mann-Whitney test was used to determine statistical differences  
332 between DP and DN<sub>paired</sub>; *p* values considered statistically significant (*p*<0.05) are shown  
333 in bold. DP: dual-positive; DN<sub>paired</sub>: total double-negative; NA: not analyzed

334

	DP (n=14)	DN <sub>paired</sub> (n=26)	<i>p</i> value
Male, n	78.57% (11)	88.46% (23)	NA
Age, years	42 (29-51)	33 (26-43)	0.2224
HIV-1 viral load, copies/ml	147,580 (2,284-700,074)	76,298 (15,757-141,159)	0.4572
CD4+ T cell count, cell/ $\mu$ l	166 (91-450)	300 (128-472)	0.4113
CD8+ T cell count, cell/ $\mu$ l	1,008 (744-1,607)	995 (852-1,489)	0.7474
CD4+/CD8+ T cell ratio	0.21 (0.058-0.39)	0.29 (0.14-0.49)	0.3954
CD45+ T cell count, cell/ $\mu$ l	1,788 (1,262-3,054)	1,958 (1,628-2,585)	0.6641

335


336 To investigate possible associations between transmission clusters of a more-aggressive  
337 HIV subtype and worsen HIV clinical status, HIV-1 subtyping was performed in the DP  
338 and DN<sub>paired</sub> subset to infer. After excluding samples with a viral load <1,000 copies/mL,  
339 both groups were pooled together (n=19) and submitted to phylogenetic analysis using  
340 the jpHMM-HIV model (Supplementary Figure 3). Concerning subtype distribution,

341 subtype B (63.16%, 12/19) was the most prevalent, followed by subtypes C (15.79%,  
342 3/19), recombinant BF (15.79%, 3/19) and D (5.26%, 1/19). No statistical differences in  
343 subtype were observed between the DP and DN<sub>paired</sub> groups (p=0.67) (Supplementary  
344 Table 2). No transmission cluster was identified. HIV-1 subtyping showed no impact on  
345 *L. infantum* serology titers, viral load, T cell count, or any other host immunological  
346 marker evaluated, indicating that HIV-1 subtypes B, C, D, F1 and BF exhibit similar  
347 virological and immunological outcome in HIV/*L. infantum* co-infection.

348

349 Next, we quantified circulating cytokines and chemokines that might reflect an increase  
350 in systemic immune activation and have been previously associated with infection to *L.*  
351 *infantum* [46–49]. The systemic levels of cytokines tested (IL-1 $\beta$ , IL-6, IL-10, IL-12p70  
352 and TNF) were below the detection limits in all samples (DP and DN<sub>paired</sub> groups),  
353 concordant with our previous findings in a large Cuban cohort of PWH [4]. Conversely,  
354 most chemokines (except IL-8) were readily detected in most PWH, demonstrating a  
355 significant increase in CXCL10/IP-10 (p=0.0076) and a tendency towards higher  
356 CXCL9/MIG levels (p=0.061) (Figure 4) in the DP group compared to DN<sub>paired</sub>,  
357 suggesting increased immune activation in the group with DP serology for *L. infantum*.











358



359

360 **Figure 4. Chemokine profiles obtained from plasma/serum samples of DP and**  
 361 **DN<sub>paired</sub> groups.** A-E) Violin plots with dot-plot overlays illustrating chemokine plasma  
 362 levels (pg/mL). Statistical comparisons made by the Mann-Whitney test in plasma levels  
 363 (pg/mL) of CCL2/MPC-1 (p=0.43), CCL5/RANTES (p=0.94), CXCL8/IL-8 (p=0.54),  
 364 CXCL9/MIG (p=0.061) and CXCL10/IP-10 (p=0.0076) chemokines. Open squares (□):  
 365 subgroup of double-positive PWH (positive for both anti-SLA and anti-HSP70 *L.*  
 366 *infantum* antigens); open circle (○): subgroup of paired double-negative PWH  
 367 (serologically negative for anti-SLA and anti-HSP70 *L. infantum* antigens). The red

368 symbol represents the DP individual diagnosed with visceral leishmaniasis >20 years ago.  
369 F) Heat map shows the correlation (pink: positive correlation; blue: negative correlation;  
370 white: no correlation) of epidemiological, virological and immunological characteristics  
371 of PWH.  
372  
373 This finding, together with the decreased CD4<sup>+</sup> T cell counts found in our previous  
374 analysis (Table 2), corroborates the hypothesis that therapy-naïve HIV-1-infected  
375 subjects previously or currently infected with *L. infantum* exhibit a more intensified state  
376 of immune activation than HIV-1 positive, *L. infantum* seronegative subjects. During  
377 clinical follow-up, the introduction of antiretroviral therapy restored CD4<sup>+</sup> T cell counts  
378 (median values of CD4<sup>+</sup> T cell counts after 4-5 years of follow-up: DP=620 cells/ $\mu$ L and  
379 DN<sub>paired</sub>=870 cells/ $\mu$ L) and reduced viral load levels to undetectable limits similarly in  
380 each group (Figure 5), with no statistically significant differences between groups (AUC  
381 comparison, data not shown).



383 **Figure 5. Long-term follow-up of CD4<sup>+</sup>, CD8<sup>+</sup>, CD4/CD8 ratio, CD45<sup>+</sup> and viral load**  
384 **levels after therapy introduction in DP and DN<sub>paired</sub> groups.** A-J) Box plots with line  
385 plot overlays connecting medians of CD4<sup>+</sup>, CD8<sup>+</sup>, CD4/CD8 ratio, CD45<sup>+</sup> and viral load  
386 levels during follow-up. A and F) Follow-up of viral load (copies/mL) in DN<sub>paired</sub> (A) and  
387 DP (F) groups. B and G) Follow-up of CD4<sup>+</sup> T cell count (cells/ $\mu$ L) in DN<sub>paired</sub> (B) and  
388 DP (G) groups. C and H) Follow-up of CD8<sup>+</sup> T cell count (cells/ $\mu$ L) in DN<sub>paired</sub> (C) and  
389 DP (H) groups. D and I) Follow-up of CD4/CD8 (ratio) in DN<sub>paired</sub> (D) and DP (I) groups.  
390 E and J) Follow-up of CD45<sup>+</sup> T cell count (cells/ $\mu$ L) in DN<sub>paired</sub> (E) and DP (J) groups.


391

392 ***CXCL10* is shared between the HIV and visceral leishmaniasis gene signatures, while**  
393 ***CXCL10*, *CXCL9* and *CCL2* positively correlate with HIV viral load in untreated**  
394 **PWH**

395 Given the small number of immune activation markers and modest cohort size for the  
396 paired DP and DN groups, we aimed to validate and extend our findings by cross-  
397 examining independent cohorts of HIV-1 (Swiss HIV Cohort, n=137) or *Leishmania*-  
398 infected individuals with and without active disease (Piaui Northeast Brazil, n=30) with  
399 publicly available transcriptome-wide data [40,41]. As shown in Figure 6A-B, a  
400 significant overlap (41 genes, enrichment p<0.0001) was found between the HIV and  
401 visceral leishmaniasis gene signatures when comparing the top 500 transcripts  
402 significantly upregulated during active disease in both untreated HIV patients and  
403 untreated visceral leishmaniasis patients, as compared to their paired post-treatment  
404 groups. A systems biology analysis of the 41 genes shared by HIV and leishmaniasis  
405 active disease signatures revealed several significantly enriched biological processes,  
406 encompassing immune activation broadly and, more specifically, type I IFN signaling  
407 and antiviral response. The overlapping genes included *CXCL10*, which we found to be



408 overexpressed in the DP group of our prospective cohort, as well as *STAT1*, the major  
409 transcription factor activated by IFN signaling. As detailed in Figure 6A and  
410 Supplementary Tables 3-5, enriched gene sets from Molecular Signatures Database  
411 (MSigDb) representing 'immune activation' included graft-versus-host disease, antigen  
412 recognition and blister cytotoxicity, while enriched gene sets representing 'type I  
413 IFN/antiviral response' comprised those upregulated in the liver by HBV infection, by  
414 IFN-alpha treatment of fibroblasts *in vitro* and by IFN-beta treatment of multiple sclerosis  
415 patients *in vivo*. Of interest, *IFNG* transcripts significantly decrease in monoinfected  
416 visceral leishmaniasis individuals, confirming our previous results obtained at the protein  
417 level for systemic IFN- $\gamma$  in two independent VL cohorts [46,49].  
418



419

420 **Figure 6. CXCL10 is shared between the HIV and visceral leishmaniasis disease**  
 421 **signatures while CXCL10, CXCL9 and CCL2 transcripts positively correlate with**  
 422 **HIV viral load in untreated PWH. Venn diagrams show overlap between (A) active**  
 423 **disease gene signatures, i.e. genes upregulated in untreated PWH (Swiss cohorts) and**  
 424 **visceral leishmaniasis patients (as compared to post-treatment) and (B) genes upregulated**

425 in untreated PWH and asymptomatic *Leishmania*-infected individuals (who did not  
426 develop disease). Systems biology analysis shows a significant enrichment of gene sets  
427 comprising immune activation and type I IFN signaling (right-hand panels). (C) Selective  
428 up-regulation of *CXCL10* and *STAT1* (as a positive control for IFN signaling) transcripts  
429 in both untreated visceral leishmaniasis patients (upper panel) and *Leishmania infantum*-  
430 exposed individuals (D) Selective up-regulation (upper panel) and positive correlation to  
431 viral load (lower panel) of *CXCL10*, *CXCL9* and *CCL2* and *STAT1* (as a positive control  
432 for IFN signaling) transcripts in untreated PWH (Swiss cohort, n=137).

433

434 To define a specific '*Leishmania* infection' gene signature, we used the top 500  
435 significantly upregulated transcripts from *Leishmania*-infected individuals who did not  
436 develop disease, for which *Leishmania* infection was documented by a positive skin DTH  
437 reaction, as compared to matched DTH-negative individuals from the same endemic area  
438 [41]. Surprisingly, the overlap between the 'untreated HIV' and '*Leishmania*-seropositive  
439 (DP)' gene signatures was even more pronounced than the overlap between the 'untreated  
440 HIV' and 'untreated visceral leishmaniasis' gene signatures, both by quantitative (65  
441 shared genes, Figure 6B) and qualitative measures (median gene set overlap 9.4% vs  
442 3.2%, Mann-Whitney  $p < 0.0001$ , Supplementary Table 3), indicating that even  
443 asymptomatic *Leishmania* infection has a profound effect on the systemic immune  
444 response. Again, *CXCL10* and *STAT1* were shared among the two disease signatures  
445 (Figure 6B), and enriched gene sets included type I IFN signaling (genes upregulated by  
446 IFN-beta treatment of multiple sclerosis patients *in vivo* and by IFN-alpha treatment of  
447 fibroblasts *in vitro*) and immune activation (inflammatory response to LPS, TNF  
448 signaling).

449

450 Validation of our DP cohort results revealed that *CXCL10*, but not *CCL2*, *CCL5* or  
451 *CXCL8* transcripts, were significantly upregulated by *Leishmania infantum* infection with  
452 or without clinically definite visceral leishmaniasis (Figure 6C upper and lower panel).  
453 In the Swiss HIV Cohort, we found that *CXCL10*, *CCL2* and, to a lesser extent, *CXCL9*  
454 transcripts were significantly upregulated during untreated HIV-1 infection. In contrast,  
455 no significant effect was observed for *CXCL8* in either asymptomatic or symptomatic  
456 *Leishmania infantum* infection, supporting our negative findings for *CXCL8* genetic  
457 variation in visceral leishmaniasis patients from the same endemic region [47]. However,  
458 *CXCL8* transcripts were significantly downregulated during untreated HIV-1 infection  
459 (Figure 6D upper panel). Finally, as shown in Figure 6D (lower panel), *CCL2*, *CXCL9*  
460 and *CXCL10* transcripts were significantly correlated (even after stringent correction for  
461 genome-wide testing) with set point viral load in untreated PWH from the Swiss HIV  
462 Cohort (n=137), confirming the results from our prospective cross-sectional cohort  
463 (Figure 4F).

464 **DISCUSSION**

465 The geographic overlap of HIV-1 and *L. infantum* infections raises the possibility of co-  
466 infection, which several groups have shown to increase morbidity and mortality [7,11,52–  
467 58,13,14,19,21–23,50,51]. Several groups have studied the extent of this overlap in  
468 several Brazilian regions. However, no studies have attempted to determine the  
469 seroprevalence of *L. infantum* among PWH in the state of Bahia, despite the significant  
470 prevalence of both infections [25,26]. We used a two-stage cross-sectional cohort  
471 approach (CSC-I, n=5,346 and CSC-II, n=317) and identified positive serology for *L.*  
472 *infantum* ranging from 4.73% (DP for anti-SLA and anti-HSP70) to 18.93% in the CSC-  
473 II (union of all positive samples for anti-SLA and anti-HSP70), with an intermediate  
474 seroprevalence for only anti-SLA of 16.27% in the CSC-I and 15.46% in the CSC-II. The  
475 observed frequencies of *Leishmania* seroprevalence in PWH using any of the serology  
476 strategies in both the cross-sectional cohorts support previous findings falling within the  
477 range of what has already been described in other Brazilian regions [9,12,20,59].  
478 Moreover, demographic data indicated that all DP patients were born in the macroregions  
479 surrounding the cities of Salvador and Feira de Santana, which are responsible for 33.8%  
480 (1,074/3,172) of notified VL cases in Bahia between 2007 and 2015 [25].

481

482 The observed discrepancy between the results obtained with the two different  
483 immunoassays might be explained by the rigor employed to determine cutoffs for each  
484 serological test and the imbalance in protein fractions between these two antigen-based  
485 diagnostic methods. SLA is a heterogeneous mix of antigens and has a lower  
486 concentration of HSP70 than parasite structural proteins (actin, tubulin, etc.). Even  
487 though it will pick up a broader set of samples, some samples with low antibody levels  
488 will fail. On the other hand, the recombinant HSP70 antigen is homogenous and highly

489 concentrated and has a better detection limit. We considered only those samples  
490 demonstrating dual positivity to increase confidence regarding past or present *L. infantum*  
491 infection. This strategy was underscored by the identification of one individual with a  
492 previous history of VL in the DP group and no cases with an earlier history of VL in the  
493 DN<sub>paired</sub> group.

494  
495 Unfortunately, only serum or plasma samples were available for HIV-1 RNA extraction,  
496 thus precluding DNA analysis to detect *L. infantum* by qPCR, which we acknowledge as  
497 a limitation of our study. However, Fukutani *et al.* (2014) [60] demonstrated a  
498 concordance of 68% between anti-SLA serology and PCR, and found a 5.40% rate of  
499 ongoing asymptomatic *L. infantum* infection among blood donors in Salvador, Bahia.  
500 Nevertheless, positive IgG serology for *L. infantum* indicates immunological memory of  
501 at least a previous *Leishmania* infection before HIV diagnosis. Strikingly, we identified  
502 a DP individual with a pronounced humoral response two decades after a VL clinical  
503 diagnosis. This ongoing humoral response most likely reflects chronic antigen exposure,  
504 emphasizing the concept that *Leishmania* infection is lifelong in most patients, as well as  
505 murine models of disease [43–45]. A wealth of studies worldwide [14,42,61–64] and a  
506 recent systematic review [56] have demonstrated a high frequency of relapse of VL in  
507 PWH, as well as increased mortality. Relapse of VL have been reported after anti-  
508 leishmaniasis treatment, even years after the patient was considered clinically cured,  
509 especially in PWH and/or immunosuppressive conditions [13,51].

510  
511 Prior large studies, including from our group, have found striking differences in the  
512 prevalence of VL within different regions in Brazil, as well as Southern Europe. The  
513 highest seroprevalence was observed in Mato Grosso, 41.40% of blood donors, in contrast

514 to other regions in Brazil (Salvador: 5.40% of 700 [60]; Paraná: 11.40% of 176 [65];  
515 Fortaleza: 17.10% of 431 [66]), and in Southern Europe (France: 13.40% of 565 [67];  
516 Spain: 3.10% of 1,437 [68]).

517

518 Studies conducted in populations of newly diagnosed HIV-1-infected individuals from  
519 regions endemic for leishmaniasis in Brazil reported a prevalence of HIV-1/*L. infantum*  
520 co-infection ranging from 4.20% to 20.20%. In these studies, *L. infantum* infection was  
521 determined by parasitological, serological and/or molecular testing [9,12,20,59].  
522 However, in co-infection studies focused on VL patients, which were diagnosed by  
523 parasitological, molecular or immunofluorescence methods, the prevalence of HIV-1/*L.*  
524 *infantum* coinfection ranged from 36.60% to 55.60% [16–18].

525

526 The present study also investigated possible differences in the prevalence of HIV-1  
527 variants associated with *L. infantum* infection in PWH. With these subtyping results, we  
528 would like to investigate if a possible worsen disease progression in PWH with positive  
529 serology for *L. infantum* cases was related to cluster of transmission of a more-aggressive  
530 HIV subtype (e.g. HIV Subtype D) [69]. However, no differences were found concerning  
531 HIV-1 isolates between matched samples of patients infected (DP) or not (DN<sub>paired</sub>) to *L.*  
532 *infantum*. Within these isolates, subtype B (63.16%) was found to be the most prevalent,  
533 followed by C (15.79%), recombinant BF (15.79%) and D (5.26%). Recent studies in  
534 Bahia that evaluated HIV-1 variant distribution have described the wide distribution of  
535 subtype B, followed by a smaller proportion of recombinant BF units [70–72]. Of note,  
536 the higher prevalence of subtype C (15.79%) found herein stands in contrast to other  
537 studies also conducted in this region, which reported a very low prevalence ranging from  
538 1.70% to 2.50% [71,73,74].

539

540 Moreover, our confirmation of the circulation of subtype D in the state is following work  
541 by Monteiro *et al.* (2009) [75], who previously reported the presence of subtype D in  
542 individuals from Feira de Santana (0.60% of  $_{\text{pol}}\text{F}/_{\text{env}}\text{D}$  subtype), a city located ~100 km  
543 from Salvador. It is worth noting that the subtyping analysis performed herein involved  
544 three different methodologies (REGA HIV-1 Subtyping Tool, phylogeny and jpHMM-  
545 HIV probabilistic modeling), which lends support to the presently reported distribution.  
546 Furthermore, our subtype identification was performed using HIV-1 *pol* sequences,  
547 inferring subtype frequencies can vary when complete genome sequencing is performed.

548

549 Prior research into host immune responses has demonstrated that *L. infantum* infection  
550 induces a higher level of immune activation in co-infected PWH, which could lead to a  
551 more rapid progression to AIDS [3,76–78]. Our study found a roughly five-fold increase  
552 in circulating CXCL10/IP-10 and CXCL9/MIG chemokines in PWH exposed to *L.*  
553 *infantum*, supporting a link between positive serology for *L. infantum* and immune  
554 activation, which we validated at the transcript level for CXCL10 in independent HIV-1  
555 and *Leishmania*-infected cohorts. These chemokines are strongly induced by both type I  
556 (IFN- $\alpha/\beta$ ) and type II IFN (IFN- $\gamma$ ) [79–82]. It has been previously reported that Th1  
557 subpopulations of CD4<sup>+</sup>CD95<sup>+</sup>T cells in HIV-1 infected individuals are highly  
558 susceptible to HIV-1 envelope gp120-induced apoptosis [83,84], which may corroborate  
559 the deleterious role of intensified immune activation [85–87]. In a submitted manuscript  
560 (Khouri *et al.*), we demonstrated an increase in both systemic soluble Fas as well as  
561 membrane-bound Fas/CD95 expression in CD8<sup>+</sup> cells in HIV/VL co-infection, as  
562 compared to HIV-1 or VL mono-infected groups, in a large cohort of individuals recruited  
563 during an outbreak of VL in Piauí, another state in the same northeast region of Brazil.



564 Since we previously demonstrated STAT1-mediated IFN signaling as a preferential  
565 inducer of Fas/CD95 at both the protein and transcript level [88,89], this study as well as  
566 Khouri *et al.* (submitted) underscore the pivotal role of IFN-driven immune activation in  
567 HIV-1 and *Leishmania infantum* co-infection and its deleterious effect on both AIDS  
568 progression and visceral leishmaniasis.

569

570 The present study aimed to describe the prevalence and consequences of *L. infantum*  
571 infection in a population of antiretroviral treatment-naïve PWH at diagnosis. We found a  
572 high seroprevalence of *L. infantum* in treatment-naïve PWH in Bahia (Brazil) associated  
573 with a more intensified state of immune activation as compared to HIV-1 monoinfected  
574 subjects, possibly exacerbating progression to AIDS, which was observed in 66.67% in  
575 co-infected individuals at diagnosis. Moreover, *Leishmania*-infected PWH are at high risk  
576 of developing severe visceral leishmaniasis [56]. These findings underscore the urgent  
577 need to increase awareness and define public health strategies for the management and  
578 prevention of HIV-1 and *L. infantum* co-infection.

579 **FUNDING**

580 This work was financed in part by Fundação de Amparo à Pesquisa do Estado da Bahia  
581 (FAPESB, APP0032/2016), Coordenação de Aperfeiçoamento de Pessoal de Nível  
582 Superior (CAPES – finance code 001) and FWO (grant G0D6817N). None of the funding  
583 organizations had any role in the study design, data collection, data interpretation or  
584 writing of this report.

585

586 **ACKNOWLEDGMENTS**

587 The authors would like to thank Andris K. Walter for English language revision and  
588 manuscript copyediting assistance.

589   **REFERENCES**

- 590   1.    Costin JM. Cytopathic Mechanisms of HIV-1. *Virology*. 2007;4: 100.  
591        doi:10.1186/1743-422X-4-100
- 592   2.    Perkins MR, Bartha I, Timmer JK, Liebner JC, Wollinsky D, Günthard HF, et al.  
593        The Interplay Between Host Genetic Variation, Viral Replication, and Microbial  
594        Translocation in Untreated HIV-Infected Individuals. *J Infect Dis*. 2015;212: 578–  
595        584. doi:10.1093/infdis/jiv089
- 596   3.    Claiborne DT, Prince JL, Scully E, Macharia G, Micci L, Lawson B, et al.  
597        Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral  
598        load in memory CD4 + T cells, and disease progression. *Proc Natl Acad Sci*.  
599        2015;112: E1480–E1489. doi:10.1073/pnas.1421607112
- 600   4.    Kouri V, Khouri R, Alemán Y, Abrahantes Y, Vercauteren J, Pineda-Peña A-C, et  
601        al. CRF19\_cpx is an Evolutionary fit HIV-1 Variant Strongly Associated With  
602        Rapid Progression to AIDS in Cuba. *EBioMedicine*. 2015;2: 244–254.  
603        doi:10.1016/j.ebiom.2015.01.015
- 604   5.    van Griensven J, Ritmeijer K, Lynen L, Diro E. Visceral Leishmaniasis as an AIDS  
605        Defining Condition: Towards Consistency across WHO Guidelines. Ghedin E,  
606        editor. *PLoS Negl Trop Dis*. 2014;8: e2916. doi:10.1371/journal.pntd.0002916
- 607   6.    World Health Organization. Investing To Overcome the Global Impact of  
608        Neglected Tropical Diseases: third WHO Report on Neglected Tropical Diseases.  
609        2015.
- 610   7.    Coura-Vital W, Araújo VEM de, Reis IA, Amancio FF, Reis AB, Carneiro M.  
611        Prognostic Factors and Scoring System for Death from Visceral Leishmaniasis: An  
612        Historical Cohort Study in Brazil. Santiago H da C, editor. *PLoS Negl Trop Dis*.  
613        2014;8: e3374. doi:10.1371/journal.pntd.0003374

- 614 8. Leite de Sousa-Gomes M, Nilce Silveira Maia-Elkhoury A, Maria Pelissari D,  
615 Edilson Ferreira de Lima Junior F, Martins de Sena J, Paula Cechinel M.  
616 Coinfecção Leishmania-HIV no Brasil: aspectos epidemiológicos, clínicos e  
617 laboratoriais. *Epidemiol e Serviços Saúde*. 2011;20: 519–526. doi:10.5123/S1679-  
618 49742011000400011
- 619 9. Carranza-Tamayo CO, Assis TSM de, Neri ATB, Cupolillo E, Rabello A, Romero  
620 GAS. Prevalence of Leishmania infection in adult HIV/AIDS patients treated in a  
621 tertiary-level care center in Brasilia, Federal District, Brazil. *Trans R Soc Trop  
622 Med Hyg*. 2009;103: 743–748. doi:10.1016/j.trstmh.2009.01.014
- 623 10. Távora LGF, Nogueira MB, Gomes ST. Visceral Leishmaniasis/HIV co-infection  
624 in northeast Brazil: evaluation of outcome. *Brazilian J Infect Dis*. 2015;19: 651–  
625 656. doi:10.1016/j.bjid.2015.07.004
- 626 11. Diniz LFB, de Souza CDF, do Carmo RF. Epidemiology of human visceral  
627 leishmaniasis in the urban centers of the lower-middle São Francisco Valley,  
628 Brazilian semiarid region. *Rev Soc Bras Med Trop*. 2018;51: 461–466.  
629 doi:10.1590/0037-8682-0074-2018
- 630 12. Carvalho FL, Aires DLS, Segunda ZF, Azevedo CMPES De, Corrêa RDGCF,  
631 Aquino DMC de, et al. Perfil epidemiológico dos indivíduos HIV positivo e  
632 coinfecção HIV-Leishmania em um serviço de referência em São Luís, MA, Brasil.  
633 *Cien Saude Colet*. 2013;18: 1305–1312. doi:10.1590/S1413-81232013000500015
- 634 13. Silva de Lima UR, Vanolli L, Moraes EC, Ithamar JS, Pedrozo e Silva de Azevedo  
635 C de M. Visceral leishmaniasis in Northeast Brazil: What is the impact of HIV on  
636 this protozoan infection? *PLoS One*. 2019;14: 1–14.  
637 doi:10.1371/journal.pone.0225875
- 638 14. Luz JGG, Naves DB, de Carvalho AG, Meira GA, Dias JVL, Fontes CJF. Visceral

- 639 leishmaniasis in a Brazilian endemic area: An overview of occurrence, HIV  
640 coinfection and lethality. *Rev Inst Med Trop Sao Paulo*. 2018;60: 1–9.  
641 doi:10.1590/S1678-9946201860012
- 642 15. Botelho ACA, Natal D. Primeira descrição epidemiológica da leishmaniose  
643 visceral em Campo Grande, Estado de Mato Grosso do Sul. *Rev Soc Bras Med*  
644 *Trop*. 2009;42: 503–508. doi:10.1590/S0037-86822009000500006
- 645 16. Druzian AF, Souza AS de, Campos DN de, Croda J, Higa MG, Dorval MEC, et al.  
646 Risk Factors for Death from Visceral Leishmaniasis in an Urban Area of Brazil.  
647 *PLoS Negl Trop Dis*. 2015;9: e0003982. doi:10.1371/journal.pntd.0003982
- 648 17. Cota GF, de Sousa MR, de Mendonça ALP, Patrocinio A, Assunção LS, de Faria  
649 SR, et al. Leishmania-HIV Co-infection: Clinical Presentation and Outcomes in an  
650 Urban Area in Brazil. Debrabant A, editor. *PLoS Negl Trop Dis*. 2014;8: e2816.  
651 doi:10.1371/journal.pntd.0002816
- 652 18. Souza GF de, Biscione F, Greco DB, Rabello A. Slow clinical improvement after  
653 treatment initiation in Leishmania/HIV coinfecting patients. *Rev Soc Bras Med*  
654 *Trop*. 2012;45: 147–150. doi:10.1590/S0037-86822012000200001
- 655 19. Sousa JM dos S, Ramalho WM, De Melo MA. Demographic and clinical  
656 characterization of human visceral leishmaniasis in the State of Pernambuco,  
657 Brazil between 2006 and 2015. *Rev Soc Bras Med Trop*. 2018;51: 622–630.  
658 doi:10.1590/0037-8682-0047-2018
- 659 20. Soares VYR, Lúcio Filho CEP, Carvalho LIM de, Silva AMM de M e, Eulálio KD.  
660 Clinical and epidemiological analysis of patients with HIV/AIDS admitted to a  
661 reference hospital in the northeast region of Brazil. *Rev Inst Med Trop Sao Paulo*.  
662 2008;50: 327–332. doi:10.1590/S0036-46652008000600003
- 663 21. Lima ÁLM, de Lima ID, Coutinho JFV, de Sousa ÚPST, Rodrigues MAG, Wilson

- 664 ME, et al. Changing epidemiology of visceral leishmaniasis in northeastern Brazil:  
665 A 25-year follow-up of an urban outbreak. *Trans R Soc Trop Med Hyg.* 2017;111:  
666 440–447. doi:10.1093/trstmh/trx080
- 667 22. Lima ID, Lima ALM, Mendes-Aguiar C de O, Coutinho JFV, Wilson ME, Pearson  
668 RD, et al. Changing demographics of visceral leishmaniasis in northeast Brazil:  
669 Lessons for the future. *PLoS Negl Trop Dis.* 2018;12: 1–16.  
670 doi:10.1371/journal.pntd.0006164
- 671 23. Santos GDO, De Jesus NPS, Cerqueira-Braz JV, Santos VS, De Lemos LMD.  
672 Prevalence of HIV and associated factors among visceral leishmaniasis cases in an  
673 endemic area of Northeast Brazil. *Rev Soc Bras Med Trop.* 2019;52: 1–4.  
674 doi:10.1590/0037-8682-0257-2018
- 675 24. Albuquerque LCP de, Mendonça IR, Cardoso PN, Baldaçara LR, Borges MRMM,  
676 Borges J da C, et al. HIV/AIDS-related visceral leishmaniasis: a clinical and  
677 epidemiological description of visceral leishmaniasis in northern Brazil. *Rev Soc*  
678 *Bras Med Trop.* 2014;47: 38–46. doi:10.1590/0037-8682-0180-2013
- 679 25. Secretaria de Saúde do Estado da Bahia. Informe Epidemiológico de Leishmaniose  
680 Visceral, Bahia. 2018.
- 681 26. Secretaria Municipal de Saúde de Salvador. Boletim Epidemiológico de AIDS:  
682 Situação Epidemiológica da AIDS em Salvador, Bahia. 2019.
- 683 27. Charlab R, Barral-Netto M, Valenzuela JG, Barral A, Caldas A, Honda E, et al.  
684 Human immune response to sand fly salivary gland antigens: a useful  
685 epidemiological marker? *Am J Trop Med Hyg.* 2000;62: 740–745.  
686 doi:10.4269/ajtmh.2000.62.740
- 687 28. Souza AP, Soto M, Costa JML, Boaventura VS, de Oliveira CI, Cristal JR, et al.  
688 Towards a More Precise Serological Diagnosis of Human Tegumentary

- 689 Leishmaniasis Using Leishmania Recombinant Proteins. Zamboni DS, editor.  
690 PLoS One. 2013;8: e66110. doi:10.1371/journal.pone.0066110
- 691 29. Soto M, Corvo L, Garde E, Ramírez L, Iniesta V, Bonay P, et al. Coadministration  
692 of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA  
693 Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice.  
694 Melby PC, editor. PLoS Negl Trop Dis. 2015;9: e0003751.  
695 doi:10.1371/journal.pntd.0003751
- 696 30. Barreto CC, Nishyia A, Araújo L V., Ferreira JE, Busch MP, Sabino EC. Trends  
697 in antiretroviral drug resistance and clade distributions among HIV-1-infected  
698 blood donors in Sao Paulo, Brazil. J Acquir Immune Defic Syndr. 2006;41: 338–  
699 341. doi:10.1097/01.qai.0000199097.88344.50
- 700 31. Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, et al. Extensive  
701 polymorphisms observed in HIV-1 clade B protease gene using high-density  
702 oligonucleotide arrays. Nat Med. 1996;2: 753–759. doi:10.1038/nm0796-753
- 703 32. Pieniazek D, Peralta JM, Ferreira JA, Krebs JW, Owen SM, Sion FS, et al.  
704 Identification of mixed HIV-1/HIV-2 infections in Brazil by polymerase chain  
705 reaction. AIDS. 1991;5: 1293–1300. doi:10.1097/00002030-199111000-00002
- 706 33. Frenkel LM, Wagner LE, Atwood SM, Cummins TJ, Dewhurst S. Specific,  
707 sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations  
708 associated with resistance to zidovudine and didanosine. J Clin Microbiol.  
709 1995;33: 342–347. doi:10.1128/jcm.33.2.342-347.1995
- 710 34. Janini LM, Pieniazek D, Peralta JM, Schechter M, Tanuri A, Vicente ACP, et al.  
711 Identification of single and dual infections with distinct subtypes of human  
712 immunodeficiency virus type 1 by using restriction fragment length polymorphism  
713 analysis. Virus Genes. 1996;13: 69–81. doi:10.1007/BF00576981

- 714 35. Schultz A-K, Zhang M, Bulla I, Leitner T, Korber B, Morgenstern B, et al.  
715 jpHMM: Improving the reliability of recombination prediction in HIV-1. *Nucleic*  
716 *Acids Res.* 2009;37: W647–W651. doi:10.1093/nar/gkp371
- 717 36. Guindon S, Dufayard J-F, Lefort V, Anisimova M, Hordijk W, Gascuel O. New  
718 Algorithms and Methods to Estimate Maximum-Likelihood Phylogenies:  
719 Assessing the Performance of PhyML 3.0. *Syst Biol.* 2010;59: 307–321.  
720 doi:10.1093/sysbio/syq010
- 721 37. Vivarini áislan de C, Calegari-Silva TC, Saliba AM, Boaventura VS, França-Costa  
722 J, Khouri R, et al. Systems Approach Reveals Nuclear Factor Erythroid 2-Related  
723 Factor 2/Protein Kinase R Crosstalk in Human Cutaneous Leishmaniasis. *Front*  
724 *Immunol.* 2017;8: 1–18. doi:10.3389/fimmu.2017.01127
- 725 38. Subramanian K, Dierckx T, Khouri R, Menezes SM, Kagdi H, Taylor GP, et al.  
726 Decreased RORC expression and downstream signaling in HTLV-1-associated  
727 adult T-cell lymphoma/leukemia uncovers an antiproliferative IL17 link: A  
728 potential target for immunotherapy? *Int J Cancer.* 2019;144: 1664–1675.  
729 doi:10.1002/ijc.31922
- 730 39. Delgobo M, Mendes DAGB, Kozlova E, Rocha EL, Rodrigues-Luiz GF, Mascarin  
731 L, et al. An evolutionary recent IFN/IL-6/CEBP axis is linked to monocyte  
732 expansion and tuberculosis severity in humans. *Elife.* 2019;8: 1–32.  
733 doi:10.7554/eLife.47013
- 734 40. Rotger M, Dang KK, Fellay J, Heinzen EL, Feng S, Descombes P, et al. Genome-  
735 Wide mRNA Expression Correlates of Viral Control in CD4+ T-Cells from HIV-  
736 1-Infected Individuals. Emerman M, editor. *PLoS Pathog.* 2010;6: e1000781.  
737 doi:10.1371/journal.ppat.1000781
- 738 41. Gardinassi LG, Garcia GR, Costa CHN, Costa Silva V, de Miranda Santos IKF.



- 739 Blood Transcriptional Profiling Reveals Immunological Signatures of Distinct  
740 States of Infection of Humans with *Leishmania infantum*. Acosta-Serrano A,  
741 editor. PLoS Negl Trop Dis. 2016;10: e0005123.  
742 doi:10.1371/journal.pntd.0005123
- 743 42. Zacarias DA, Rolão N, de Pinho FA, Sene I, Silva JC, Pereira TC, et al. Causes  
744 and consequences of higher *Leishmania infantum* burden in patients with kala-  
745 azar: a study of 625 patients. Trop Med Int Heal. 2017;22: 679–687.  
746 doi:10.1111/tmi.12877
- 747 43. Bogdan C, Donhauser N, Döring R, Röllinghoff M, Diefenbach A, Rittig MG.  
748 Fibroblasts as host cells in latent leishmaniosis. J Exp Med. 2000;191: 2121–2129.  
749 doi:10.1084/jem.191.12.2121
- 750 44. Paduch K, Debus A, Rai B, Schleicher U, Bogdan C. Resolution of Cutaneous  
751 Leishmaniasis and Persistence of *Leishmania major* in the Absence of Arginase 1  
752 . J Immunol. 2019;202: 1453–1464. doi:10.4049/jimmunol.1801249
- 753 45. Seyed N, Peters NC, Rafati S. Translating observations from Leishmanization into  
754 non-living vaccines: The potential of dendritic cell-based vaccination strategies  
755 against *Leishmania*. Front Immunol. 2018;9: 1–10.  
756 doi:10.3389/fimmu.2018.01227
- 757 46. Caldas A, Favali C, Aquino D, Vinhas V, van Weyenbergh J, Brodskyn C, et al.  
758 Balance of IL-10 and interferon- $\gamma$  plasma levels in human visceral leishmaniasis:  
759 Implications in the pathogenesis. BMC Infect Dis. 2005;5: 1–9. doi:10.1186/1471-  
760 2334-5-113
- 761 47. Frade AF, Oliveira LC de, Costa DL, Costa CHN, Aquino D, Van Weyenbergh J,  
762 et al. TGFB1 and IL8 gene polymorphisms and susceptibility to visceral  
763 leishmaniasis. Infect Genet Evol. 2011;11: 912–916.

- 764 doi:10.1016/j.meegid.2011.02.014
- 765 48. Carneiro MW, Fukutani KF, Andrade BB, Curvelo RP, Cristal JR, Carvalho AM,  
766 et al. Gene Expression Profile of High IFN- $\gamma$  Producers Stimulated with  
767 *Leishmania braziliensis* Identifies Genes Associated with Cutaneous  
768 Leishmaniasis. McDowell MA, editor. PLoS Negl Trop Dis. 2016;10: e0005116.  
769 doi:10.1371/journal.pntd.0005116
- 770 49. Peruhype-Magalhães V, Martins-Filho OA, Prata A, Silva LDA, Rabello A,  
771 Teixeira-Carvalho A, et al. Mixed inflammatory/regulatory cytokine profile  
772 marked by simultaneous raise of interferon- $\gamma$  and interleukin-10 and low frequency  
773 of tumour necrosis factor- $\alpha$ + monocytes are hallmarks of active human visceral  
774 Leishmaniasis due to *Leishmania chagasi* infectio. Clin Exp Immunol. 2006;146:  
775 124–132. doi:10.1111/j.1365-2249.2006.03171.x
- 776 50. Botana L, Ibarra-Meneses AV, Sánchez C, Castro A, Martin JVS, Molina L, et al.  
777 Asymptomatic immune responders to *Leishmania* among HIV positive patients.  
778 PLoS Negl Trop Dis. 2019;13: 1–14. doi:10.1371/journal.pntd.0007461
- 779 51. Horrillo L, Castro A, Matía B, Molina L, García-Martínez J, Jaqueti J, et al.  
780 Clinical aspects of visceral leishmaniasis caused by *L. infantum* in adults. Ten  
781 years of experience of the largest outbreak in Europe: what have we learned?  
782 Parasit Vectors. 2019;12: 359. doi:10.1186/s13071-019-3628-z
- 783 52. Ana Nilce S M, Adolfo G, Romero S, Samantha YOB, Lindoso AL, Elisa C, et al.  
784 Premature deaths by visceral leishmaniasis in Brazil investigated through a cohort  
785 study: A challenging opportunity? PLoS Negl Trop Dis. 2019;13: 1–18.  
786 doi:<https://doi.org/10.1371/journal.pntd.0007841>
- 787 53. Van Griensven J, van Henten S, Mengesha B, Kassa M, Adem E, Seid ME, et al.  
788 Longitudinal evaluation of asymptomatic *Leishmania* infection in HIV-infected

- 789 individuals in North-West Ethiopia: A pilot study. *PLoS Negl Trop Dis.* 2019;13:  
790 30–45. doi:10.1371/journal.pntd.0007765
- 791 54. Diro E, Edwards T, Ritmeijer K, Fikre H, Abongomera C, Kibret A, et al. Long  
792 term outcomes and prognostics of visceral leishmaniasis in hiv infected patients  
793 with use of pentamidine as secondary prophylaxis based on CD4 level: A  
794 prospective cohort study in Ethiopia. *PLoS Negl Trop Dis.* 2019;13: 1–17.  
795 doi:10.1371/journal.pntd.0007132
- 796 55. Prestes-Carneiro LE, Spir PRN, Fontanesi M, Pereira Garcia KG, Silva FA Da,  
797 Flores EF, et al. Unusual manifestations of visceral leishmaniasis in children: A  
798 case series and its spatial dispersion in the western region of São Paulo state,  
799 Brazil. *BMC Infect Dis.* 2019;19: 1–9. doi:10.1186/s12879-018-3652-1
- 800 56. Fontoura IG, Barbosa DS, de Andrade Paes AM, Santos FS, Neto MS, Fontoura  
801 VM, et al. Epidemiological, clinical and laboratory aspects of human visceral  
802 leishmaniasis (HVL) associated with human immunodeficiency virus (HIV)  
803 coinfection: a systematic review – CORRIGENDUM. *Parasitology.* 2018;145:  
804 1819–1819. doi:10.1017/S0031182018001166
- 805 57. Rezaei Z, Sarkari B, Dehghani M, Layegh Gigloo A, Afrashteh M. High frequency  
806 of subclinical *Leishmania* infection among HIV-infected patients living in the  
807 endemic areas of visceral leishmaniasis in Fars province, southern Iran. *Parasitol*  
808 *Res.* 2018;117: 2591–2595. doi:10.1007/s00436-018-5949-9
- 809 58. Viana GM de C, da Silva MACN, Garcia JV de S, Guimarães HD, Arcos Júnior  
810 GF, Santos AVA, et al. Epidemiological profile of patients co-infected with  
811 visceral leishmaniasis and HIV/AIDS in northeast, Brazil. *Rev Soc Bras Med Trop.*  
812 2017;50: 613–620. doi:10.1590/0037-8682-0494-2017
- 813 59. Orsini M, Canela JR, Disch J, Maciel F, Greco D, Toledo A, et al. High frequency

- 814 of asymptomatic *Leishmania* spp. infection among HIV-infected patients living in  
815 endemic areas for visceral leishmaniasis in Brazil. *Trans R Soc Trop Med Hyg.*  
816 2012;106: 283–288. doi:10.1016/j.trstmh.2012.01.008
- 817 60. Fukutani KF, Figueiredo V, Celes FS, Cristal JR, Barral A, Barral-Netto M, et al.  
818 Serological survey of *Leishmania* infection in blood donors in Salvador,  
819 Northeastern Brazil. *BMC Infect Dis.* 2014;14: 422. doi:10.1186/1471-2334-14-  
820 422
- 821 61. Oryan A, Akbari M. Worldwide risk factors in leishmaniasis. *Asian Pac J Trop*  
822 *Med.* 2016;9: 925–932. doi:10.1016/j.apjtm.2016.06.021
- 823 62. Grande E, Zucchetto A, Suligoi B, Grippo F, Pappagallo M, Virdone S, et al.  
824 Multiple cause-of-death data among people with AIDS in Italy: A nationwide  
825 cross-sectional study. *Popul Health Metr.* 2017;15: 1–12. doi:10.1186/s12963-  
826 017-0135-3
- 827 63. Bruhn FRP, Morais MHF, Bruhn NCP, Cardoso DL, Ferreira F, Rocha CMBM.  
828 Human visceral leishmaniasis: Factors associated with deaths in Belo Horizonte,  
829 Minas Gerais state, Brazil from 2006 to 2013. *Epidemiol Infect.* 2018;146: 565–  
830 570. doi:10.1017/S0950268818000109
- 831 64. Guedes DL, Medeiros Z, Da Silva ED, De Vasconcelos AVM, Da Silva MS, Da  
832 Silva MAL, et al. Visceral leishmaniasis in hospitalized HIV-infected patients in  
833 Pernambuco, Brazil. *Am J Trop Med Hyg.* 2018;99: 1541–1546.  
834 doi:10.4269/ajtmh.17-0787
- 835 65. Braga L de S, Navasconi TR, Leatte EP, Skraba CM, Silveira TGV, Ribas-Silva  
836 RC. Presence of anti-*Leishmania (viannia) braziliensis* antibodies in blood donors  
837 in the west-central region of the state of Paraná, Brazil. *Rev Soc Bras Med Trop.*  
838 2015;48: 622–625. doi:10.1590/0037-8682-0043-2015

- 839 66. Monteiro DCS, Sousa AQ, Lima DM, Fontes RM, Praciano CC, Frutuoso MS, et  
840 al. Leishmania infantum Infection in Blood Donors, Northeastern Brazil. Emerg  
841 Infect Dis. 2016;22: 739–740. doi:10.3201/eid2204.150065
- 842 67. le Fichoux Y, Quaranta JF, Aufeuve JP, Lelievre A, Marty P, Suffia I, et al.  
843 Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors  
844 living in an area of endemicity in southern France. J Clin Microbiol. 1999;37:  
845 1953–7.
- 846 68. de Oliveira França A, Pompilio MA, Pontes ERJC, de Oliveira MP, Pereira LOR,  
847 Lima RB, et al. Leishmania infection in blood donors: A new challenge in  
848 leishmaniasis transmission? PLoS One. 2018;13: 1–13.  
849 doi:10.1371/journal.pone.0198199
- 850 69. Khouri R, Vandamme AM. Virus genetic variability involvement in  
851 transmissibility of HIV-1 immune activation and disease progression. Future Virol.  
852 2015;10: 1259–1262. doi:10.2217/fvl.15.96
- 853 70. Araujo AF, Brites C, Monteiro-Cunha J, Santos LA, Galvao–Castro B, Alcantara  
854 LCJ. Lower Prevalence of Human Immunodeficiency Virus Type 1 Brazilian  
855 Subtype B Found in Northeastern Brazil with Slower Progression to AIDS. AIDS  
856 Res Hum Retroviruses. 2010;26: 1249–1254. doi:10.1089/aid.2010.0068
- 857 71. Monteiro-Cunha JP, Araujo AF, Santos E, Galvao-Castro B, Alcantara LCJ. Lack  
858 of High-Level Resistance Mutations in HIV Type 1 BF Recombinant Strains  
859 Circulating in Northeast Brazil. AIDS Res Hum Retroviruses. 2011;27: 623–631.  
860 doi:10.1089/aid.2010.0126
- 861 72. Santos LA, Monteiro-Cunha JP, Araújo AF, Brites C, Galvão-Castro B, Alcantara  
862 LCJ. Detection of Distinct Human Immunodeficiency Virus Type 1 Circulating  
863 Recombinant Forms in Northeast Brazil. J Med Virol. 2011;83: 2066–2072.

- 864           doi:10.1002/jmv
- 865   73.   Chavez HH, Tran T-A, Dembele B, Nasreddine N, Lambotte O, Gubler B, et al.  
866           Lack of Evidence for Prolonged Double-Long Terminal Repeat Episomal HIV  
867           DNA Stability In Vivo. *JAIDS J Acquir Immune Defic Syndr.* 2007;45: 247–249.  
868           doi:10.1097/QAI.0b013e3180415dc2
- 869   74.   Santos EDS, Araújo AF, Galvão-Castro B, Alcantara LCJ. Diversidade genética  
870           do vírus da imunodeficiência humana tipo 1 (HIV-1) em mulheres infectadas de  
871           uma cidade do nordeste do Brasil. *Rev Bras Ginecol e Obs.* 2009;31: 609–614.  
872           doi:10.1590/S0100-72032009001200006
- 873   75.   Monteiro JP, Alcantara LCJ, de Oliveira T, Oliveira AM, Melo MAG, Brites C, et  
874           al. Genetic variability of human immunodeficiency virus-1 in Bahia state,  
875           Northeast, Brazil: High diversity of HIV genotypes. *J Med Virol.* 2009;81: 391–  
876           399. doi:10.1002/jmv.21414
- 877   76.   Hoffmann M, Pantazis N, Martin GE, Hickling S, Hurst J, Meyerowitz J, et al.  
878           Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary  
879           HIV-1 Infection. Wanstrom R, editor. *PLOS Pathog.* 2016;12: e1005661.  
880           doi:10.1371/journal.ppat.1005661
- 881   77.   Ipp H, Zemlin AE, Erasmus RT, Glashoff RH. Role of inflammation in HIV-1  
882           disease progression and prognosis. *Crit Rev Clin Lab Sci.* 2014;51: 98–111.  
883           doi:10.3109/10408363.2013.865702
- 884   78.   Utay NS, Hunt PW. Role of immune activation in progression to AIDS. *Curr Opin*  
885           *HIV AIDS.* 2016;11: 131–137. doi:10.1097/COH.0000000000000242
- 886   79.   Kedzierska K, Crowe SM. Cytokines and HIV-1: Interactions and Clinical  
887           Implications. *Antivir Chem Chemother.* 2001;12: 133–150.  
888           doi:10.1177/095632020101200301

- 889 80. Kenway-Lynch CS, Das A, Lackner AA, Pahar B. Cytokine/Chemokine  
890 Responses in Activated CD4+ and CD8+ T Cells Isolated from Peripheral Blood,  
891 Bone Marrow, and Axillary Lymph Nodes during Acute Simian  
892 Immunodeficiency Virus Infection. *J Virol.* 2014;88: 9442–9457.  
893 doi:10.1128/JVI.00774-14
- 894 81. Mehla R. Chemokine Deregulation in HIV Infection: Role of Interferon Gamma  
895 Induced Th1-Chemokine Signaling. *J Clin Cell Immunol.* 2013;04.  
896 doi:10.4172/2155-9899.S7-004
- 897 82. Utay NS, Douek DC. Interferons and HIV Infection: The Good, the Bad, and the  
898 Ugly. *Pathog Immun.* 2016;1: 107. doi:10.20411/pai.v1i1.125
- 899 83. Accornero P, Radrizzani M, Delia D, Gerosa F, Kurrle R, Colombo MP.  
900 Differential Susceptibility to HIV-GP120–Sensitized Apoptosis in CD4+ T-Cell  
901 Clones With Different T-Helper Phenotypes: Role of CD95/CD95L Interactions.  
902 *Blood.* 1997;89: 558–569. doi:10.1182/blood.V89.2.558
- 903 84. Cummins NW, Badley AD. Mechanisms of HIV-associated lymphocyte apoptosis:  
904 2010. *Cell Death Dis.* 2010;1: e99–e99. doi:10.1038/cddis.2010.77
- 905 85. Costa ASA, Costa GC, Aquino DMC de, Mendonça VRR de, Barral A, Barral-  
906 Netto M, et al. Cytokines and visceral leishmaniasis: a comparison of plasma  
907 cytokine profiles between the clinical forms of visceral leishmaniasis. *Mem Inst*  
908 *Oswaldo Cruz.* 2012;107: 735–739. doi:10.1590/S0074-02762012000600005
- 909 86. Rodrigues V, Cordeiro-da-Silva A, Laforge M, Silvestre R, Estaquier J. Regulation  
910 of immunity during visceral *Leishmania* infection. *Parasit Vectors.* 2016;9: 118.  
911 doi:10.1186/s13071-016-1412-x
- 912 87. Sun H, Kim D, Li X, Kiselinova M, Ouyang Z, Vandekerckhove L, et al. Th1/17  
913 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral

- 914 Therapy. Silvestri G, editor. J Virol. 2015;89: 11284–11293.  
915 doi:10.1128/JVI.01595-15
- 916 88. Khouri R, Silva-Santos G, Dierckx T, Menezes SM, Decanine D, Theys K, et al.  
917 A genetic IFN/STAT1/FAS axis determines CD4 T stem cell memory levels and  
918 apoptosis in healthy controls and Adult T-cell Leukemia patients.  
919 Oncoimmunology. 2018;7: e1426423. doi:10.1080/2162402X.2018.1426423
- 920 89. Farre L, Bittencourt AL, Silva-Santos G, Almeida A, Silva AC, Decanine D, et al.  
921 Fas-670 promoter polymorphism is associated to susceptibility, clinical  
922 presentation, and survival in adult T cell leukemia. J Leukoc Biol. 2008;83: 220–  
923 222. doi:10.1189/jlb.0407198
- 924







Figure 2 A

anti-SLA  
1998-2013





	16.27%	870
	83.73%	4476

Figure 2 B




Figure 1





Figure 3 A

anti-SLA  
2014-2015






	15.46%	49
	84.54%	268

Figure 3 B


anti-HSP70  
2014-2015



■ 8.20% 26  
■ 91.80% 291

Figure 3 C

**anti-SLA**



**anti-HSP70**

Figure 3 D




Figure 4 A






Figure 4 B




Figure 4 C




Figure 4 D





Figure 4 E

HIV untreated up

VL active disease



Gene Set Name

overlap

p-value

FDR

UP\_BY\_HBV\_INFECTION

0.097

1.41E-17

4.65E-14

INTERFERON\_RESPONSIVE\_GENES

0.1

8.14E-13

8.96E-10

RESPONSE\_TO\_IFNG\_UP

0.093

1.85E-12

1.52E-09

IFNB1\_TARGETS

0.075

9.38E-12

6.19E-09

GRAFT\_VERSUS\_HOST\_DISEASE\_D7\_UP

0.063

3.27E-11

1.35E-08

ANTIGEN\_RESPONSE

0.025

1.30E-10

4.30E-08

BLISTER\_CYTOTOXICITY\_UP

0.044

7.56E-09

1.31E-06

GRAFT\_VERSUS\_HOST\_DISEASE\_35D\_UP


0.043

8.62E-09

1.42E-06

Figure 6 A






HIV untreated up Leishmania exposed



Gene Set Name	overlap	p-value	FDR
IFNB1_TARGETS	0.37	1.04E-77	3.42E-74
INTERFERON_INDUCED_ANTIVIRAL_MODULE	0.36	4.53E-61	4.98E-58
INTERFERON_RESPONSIVE_GENES	0.39	1.80E-57	1.49E-54
IFNA_RESPONSE	0.61	6.84E-47	3.76E-44
INFLAMMATORY_RESPONSE_LPS	0.069	2.12E-43	8.75E-41
TNF_SIGNALING_UP	0.12	1.36E-16	1.02E-14
INFLAMMATORY_RESPONSE_LPS_UP	0.035	3.27E-15	2.30E-13
RESPONSE_TO_LPS_WITH_MECHANICAL_VENTILATION	0.082	7.35E-15	5.06E-13

Figure 6 B

# Leishmania active disease UP

Gene	logFC	p value	FDR
CCL2	 -0.14	0.15	0.47
CCL5	 0.38	0.20	0.52
CXCL8	 -0.16	0.06	0.32
CXCL9	ND	NA	NA
CXCL10	 0.81	0.00003	0.0027
STAT1	 1.18	0.00002	0.0024

# Leishmania-exposed UP






Gene	logFC	p value	FDR
CCL2	 0.04	0.21	0.89
CCL5	 -0.11	0.39	0.95
CXCL8	 -0.12	0.2	0.890
CXCL9	ND	NA	NA
CXCL10	 0.14	0.0089	0.59
STAT1	 0.45	0.011	0.62

Figure 6 C



# HIV untreated UP

medRxiv preprint doi: <https://doi.org/10.1101/2021.10.03.21264311>; this version posted October 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Gene	logFC	p value	FDR
CCL2	0.25	0.0019	0.10
CCL5	0.01	0.96	0.99
CXCL8	-0.60	0.0021	0.10
CXCL9	0.03	0.017	0.27
CXCL10	0.15	0.030	0.32
STAT1	0.15	0.030	0.32

# Correlation HIV viral load set point

Gene	Spearman's R	p value	FDR
CCL2	0.31	0.00047	0.04
CCL5	0.16	0.076	0.29
CXCL8	-0.13	0.14	0.55
CXCL9	0.3	0.00052	0.08
CXCL10	0.43	6.23E-07	6.90E-04
STAT1	0.5	6.33E-09	3.82E-06

Figure 6 D






Figure 4 F




Figure 5 A




Figure 5 B




Figure 5 C




Figure 5 D




Figure 5 E




Figure 5 F




Figure 5 G






Figure 5 H




Figure 5 I




Figure 5 J